Glenmark gets USFDA nod for anti-cholesterol drug
Glenmark has been granted final approval by the USFDA for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg
- IndiGo, Air India Express among Top 5 cheapest airlines in the world
- Goldman Sachs’ ReNew Power stake sale to be biggest IPO exit by a PE firm in India
- Govt may tell Tata Tele to settle dues before deal with Tata Communications
- New India Assurance looks to lower health-loss ratio to 95%
- DLF sells office space in Gurugram for Rs150 crore
New Delhi: Drug firm Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the United States Food and Drug Administration (USFDA) for its generic version of Fenofibrate capsules used for lowering cholesterol.
The company has been granted final approval by the USFDA for Fenofibrate Capsules USP 67 mg, 134 mg and 200 mg, Glenmark Pharmaceuticals said in a statement.
The company’s product is the generic version of Tricor Micronized capsules, 67 mg, 134 mg, and 200 mg of AbbVie Inc, it added. Citing IMS Health February 2017, Glenmark said the Tricor Micronized capsules had annual sales of approximately $97.5 million.
The stock was trading at Rs869.20, up 0.74% on the Bombay Stock Exchange (BSE).
Editor's Picks »
- Motherson Sumi continues to face margin pressure in foreign markets
- What the Warren Buffett indicator tells us about market valuations today
- Jet Airways lands with a thud in Q4 as fuel costs increase
- IBC amendments: Some dilutions, and a lot more speed
- Patanjali’s gambit is paying off in toothpaste wars